List view / Grid view
Acalabrutinib (rINN, ACP-196) is a novel experimental anti-cancer drug and a 2nd generation Bruton’s tyrosine kinase (BTK) inhibitor developed by Acerta Pharma, AstraZeneca‘s haematology R&D centre of excellence.
Dr Mehrdad Mobasher, Chief Medical Officer for Hematology, BeiGene, discusses the evolution of therapies for chronic lymphocytic leukaemia (CLL), the promise of targeted treatments and what could be on the horizon of the therapeutic landscape for this disease.
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...
It has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation...
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
Following the news earlier this week that AstraZeneca had been in acquisition talks with Acerta Pharma, AstraZeneca today announced that it is to invest in a majority equity stake in the company.
AstraZeneca today confirmed that it is in talks with Acerta Pharma to acquire the company in a potential deal worth $5 billion.
